Searchable abstracts of presentations at key conferences in endocrinology

ea0042p17 | (1) | Androgens2016

Next generation sequencing panels to predict response to hormonal therapy in prostate cancer

Kallio Heini M L , Annala Matti , Brofeldt Anniina , Hieta Reija , Kivinummi Kati , Tammela Teuvo , Nykter Matti , Lilja Hans G , Bova G Steven , Visakorpi Tapio

Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related death among men in Europe. Although most PCs grow slowly, 20–25% of the patients believed to have organ-confined disease will experience biochemical recurrence already during 5-years of follow-up. The standard treatment against advanced PC is androgen deprivation (ADT). Unfortunately, androgen deprivation treatment eventually fails leading to the emergence of castration resist...

ea0063p877 | Adrenal and Neuroendocrine Tumours 3 | ECE2019

Accuracy of adrenal imaging studies in predicting histological tumor dimension following adrenalectomy

Alexandraki Krystallenia , Aggeli Chrysanthi , Antonopoulou Ioanna , Parianos Christos , Ntokos George , Pateas Konstantinos , Kaltsas Gregory , Zografos Georgios

Introduction: Although computed tomography (CT) is the best mean to identify adrenal neoplasms there is still controversy of the concordance of the estimated radiological and histological size of the lesion. Since the size of adrenal tumours is a major criterion for surgical excision, we investigated whether recent and more sophisticated imaging techniques, can more accurately predict tumor’s size.Methods: We have retrospectively analyzed a series o...

ea0081p120 | Endocrine-Related Cancer | ECE2022

Novel panels of tissue microRNAs to diagnose adrenocortical malignancy based on artificial intelligence tools

Turai Peter , Herold Zoltan , Nyiro Gabor , Borka Katalin , Micsik Tamas , Toke Judit , Szucs Nikolette , Toth Miklos , Patocs Attila , Igaz Peter

Adrenocortical tumors are common, occuring in 5-7% of the population. Adrenocortical carcinoma (ACC) is rare (0.7-2/million/year) and it has a poor prognosis with a five-year survival of less than 30% in advanced stages. The histological differentiation of benign and malignant adrenocortical tumors is challenging.Objectives: To explore the diagnostic utility of multiple microRNAs in various combinations as markers of adrenocortical malignancy by using ar...

ea0094p198 | Endocrine Cancer and Late Effects | SFEBES2023

Evaluation of a national genetic testing service for monogenic endocrine disease in Scotland; enforcement of referral criteria may result in missed opportunities for genetic diagnosis

Ahmed Sufia , McLean Joanne , Berg Jonathan , Goudie David , Newey Paul

Background: Establishing a genetic diagnosis in patients presenting with potential monogenic endocrine disorders can provide benefits for the individual and wider family. Next-generation sequencing (NGS) gene panels provide a time- and cost-efficient platform for testing. A Scottish NGS endocrine testing platform, comprising 30 genes (11 individual panels), was established in 2018. A national genomic test-directory provides eligibility criteria for testing, bu...

ea0063s1.1 | Thyroid in cancer | ECE2019

What is the value of molecular markers in nodules?

Fugazzola Laura

Cytological evaluation establishes the diagnosis of a benign or malignant nodule in 70–80% of all cases, but the remaining cases lack the features needed for a definitive diagnosis. Molecular tests have been developed to assist in determining if a nodule with indeterminate cytology is benign or malignant. The first studies focused on the analysis of the most common thyroid cancer (TC) mutation, BRAFV600E. However, since many TCs are driven by other mutations, testing for ...

ea0094p234 | Neuroendocrinology and Pituitary | SFEBES2023

The utility of routine fasting gut hormone assessment in asymptomatic individuals with Multiple Endocrine Neoplasia Type 1 (MEN1)

Muhammad Tahir Chohan Dr , Chris Boot Dr , Anna L Mitchell Dr

Background: Secretory pancreatic neuroendocrine tumours (PanNET) are common in MEN1. The MEN1 Clinical Practice guideline (Thakker, 2012) recommends annual assessment of fasting gut hormones (FGH) with annual pancreatic imaging for routine NET surveillance in MEN1.Study aim: To determine whether FGH (gastrin, glucagon, somatostatin, pancreatic polypeptide, VIP, insulin, chromogranin-A) in a cohort of asymptomatic individ...

ea0041d3.1 | Strengths and weaknesses of hormone immunoassays and mass spectrometry: what the clinician should know | ECE2016

Strengths and weaknesses of hormone immunoassays and mass spectrometry: what the clinician should know: mass spectrometry

Keevil Brian

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) is a powerful tool that is changing the way we analyse steroids in the clinical laboratory. It offers positive compound identification to enable the unequivocal identification of a compound free from interference. LC–MS/MS is already opening up the field of steroid analysis in endocrinology and is providing new applications for individual steroids and panels of steroids in different clinical conditions. L...

ea0063s9.1 | Controversies in adrenal disease | ECE2019

Metanephrines: Plasma or Urine

Eisenhofer Graeme

Measurements of plasma or urinary metanephrines are recommended for diagnosis of pheochromocytoma and paraganglioma (PPGL). Differences of opinion exist concerning what test offers optimal diagnostic accuracy and whether supine sampling is required for the plasma test. Whether urinary free metanephrines offer advantages over deconjugated metabolites and the relative utilities of additional measurements of methoxytyramine are also unclear. This presentation covers 25 years of e...

ea0056p617 | Pituitary - Clinical | ECE2018

Living with acromegaly: patient journey in europe vs USA

Hey-Hadavi Judith , vanderLans Joli , Cannito Maria , Kelepouris Nicky

Introduction: Patients with acromegaly have often a challenging path from diagnosis to treatment start and to long-term care. Two separate acromegaly patient advisory panels (one in Europe and one in USA) were conducted with the aim to better learn about their experience and how this could be improved. This format was chosen to allow direct patient to patient interactions and to understand possible unmet needs and opportunities within the acromegaly community. An independent m...

ea0070ap2biog | The European Journal of Endocrinology Prize Lecture | ECE2020

EJE Award 2020 – Biography

Calebiro Davide

Davide Calebiro is a Professor of Molecular Endocrinology and Wellcome Trust Senior Research Fellow at the Institute of Metabolism and Systems Research (IMSR) and the Centre of Membrane Proteins and Receptors (COMPARE) of the University of Birmingham.He leads a multidisciplinary research team comprising biologists, chemists, physicists, engineers and computer scientists focusing on the basic mechanisms of G protein-coupled receptor (GPCR) signalling and ...